Loading...
•
Mar 31, 2024
Voyager Therapeutics Q1 2024 Earnings Report
Voyager Therapeutics reported a net loss for Q1 2024 due to decreased collaboration revenue, but announced progress in their gene therapy programs and a strong cash position.
Key Takeaways
Voyager Therapeutics reported a net loss of $11.3 million for Q1 2024, primarily due to decreased collaboration revenue compared to the same period in 2023. However, the company announced the clearance of the IND application for VY-TAU01, selection of development candidates for Neurocrine-partnered programs, and a strong cash position of approximately $400 million.
Received IND clearance for VY-TAU01 for Alzheimer’s disease and expect to begin a single ascending dose trial soon.
Development candidates were selected for Neurocrine-partnered GBA1 and Friedreich’s Ataxia gene therapy programs.
Appointed Toby Ferguson, M.D., Ph.D., as Chief Medical Officer.
Maintained a strong cash position of approximately $400 million, expected to provide runway into 2027.
Revenue by Segment
Forward Guidance
Voyager expects its cash, cash equivalents, and marketable securities, along with amounts expected to be received as reimbursement for development costs under the Neurocrine and Novartis collaborations, certain near-term milestones, and interest income, to be sufficient to meet Voyager’s planned operating expenses and capital expenditure requirements into 2027.
Positive Outlook
- Cash runway into 2027
- Reimbursement for development costs under the Neurocrine and Novartis collaborations.
- Receipt of certain near-term milestones.
- Interest income.
- Strong balance sheet
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...